Literature DB >> 8384394

Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin.

H Hart1, K Reid, W Hart.   

Abstract

A comparison of ultraviolet (UV) irradiation of two wavelength ranges UVB (280-320 nm) and UVC (lower than 280 nm) showed that UVC in particular could very effectively inactivate, in intravenous immunoglobulin (IVIG) and albumin preparations, non-enveloped and non-acid labile model viruses (i.e., Polio 2 and T4 phage) and dry heat-resistant viruses (vaccinia and T4 phage). This effective virucidal treatment (5 min, 5,000 J/m2 dose) was achieved before an unacceptable level of IVIG aggregates occurred. The use of UV irradiation to inactivate infectious agents could add safety and supplement current methods, e.g. solvent/detergent, low pH, which do not inactivate non-enveloped, non-acid labile or dry-heat-resistant viruses at present.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384394     DOI: 10.1111/j.1423-0410.1993.tb02523.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  4 in total

Review 1.  Recovery and purification process development for monoclonal antibody production.

Authors:  Hui F Liu; Junfen Ma; Charles Winter; Robert Bayer
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma.

Authors:  Axel Seltsam; Thomas H Müller
Journal:  Transfus Med Hemother       Date:  2011-01-22       Impact factor: 3.747

Review 3.  Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: A review.

Authors:  Hamada A Aboubakr; Tamer A Sharafeldin; Sagar M Goyal
Journal:  Transbound Emerg Dis       Date:  2020-07-14       Impact factor: 4.521

Review 4.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.